Compare Amphastar Pharmaceuticals Inc (AMPH) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while C.H. Robinson Worldwide, Inc. trades at $144.86 (market cap $17.33B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 20.1× Amphastar Pharmaceuticals Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CHRW | |
|---|---|---|
Market Cap | $863.95M | $17.33B |
Sector | Health | Industrials |
52-Week High | $30.81 | $209.42 |
52-Week Low | $16.87 | $116.24 |
Enterprise Value | $1.26B | $19.15B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
C.H. Robinson Worldwide (CHRW) trades at $149.35, up 1.83% on the day, with a bearish technical signal from moving averages but strong profitability metrics including a 37.12% ROE. Recent Q2 2026 earnings beat expectations with EPS of $1.61 versus $1.53 estimated, driven by pricing and efficiency gains. The stock shows support near $146 and resistance at $152, with a consensus analyst price target of $196.00 implying significant upside potential from current levels.
The outlook remains positive based on consistent earnings beats and solid fundamentals, though risks include soft freight demand and rising costs. Analyst sentiment is moderately bullish with 48% buy ratings, but investors should monitor competitive pressures and macroeconomic headwinds that could impact logistics sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
